IRE-1α inhibitors
US9981901B2 · kind B2 · utility
0Cited by
266References
2Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 18, 2016 |
| Grant date | May 29, 2018 |
| Priority date | — |
| Expiry date | Nov 18, 2036 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Compounds which directly inhibit IRE-1α activity in vitro, prodrugs, and pharmaceutically acceptable salts thereof. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response and can be used as single agents or in combination therapies.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.